Kisqali (200 MG Dose) and Vumerity
Determining the interaction of Kisqali (200 MG Dose) and Vumerity and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: The use of diroximel fumarate or dimethyl fumarate with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Both diroximel fumarate and dimethyl fumarate alone may cause lymphopenia and serious infections, and the risk may theoretically be increased due to additive immune system effects in the presence of other myelo- or immunosuppressive therapies. MANAGEMENT: The safety and efficacy of diroximel fumarate or dimethyl fumarate in combination with other immunosuppressive agents have not been evaluated. Until further information is available, the use of diroximel fumarate or dimethyl fumarate with other immunosuppressive or myelosuppressive agents should be avoided. References "Product Information. Vumerity (diroximel fumarate)." Alkermes, Inc, Cambridge, MA.
Professional:GENERALLY AVOID: The use of diroximel fumarate or dimethyl fumarate with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Both diroximel fumarate and dimethyl fumarate alone may cause lymphopenia and serious infections, and the risk may theoretically be increased due to additive immune system effects in the presence of other myelo- or immunosuppressive therapies.
MANAGEMENT: The safety and efficacy of diroximel fumarate or dimethyl fumarate in combination with other immunosuppressive agents have not been evaluated. Until further information is available, the use of diroximel fumarate or dimethyl fumarate with other immunosuppressive or myelosuppressive agents should be avoided.
- "Product Information. Vumerity (diroximel fumarate)." Alkermes, Inc, Cambridge, MA.
Generic Name: ribociclib
Brand name: Kisqali
Synonyms: Kisqali
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Kisqali (200 MG Dose)-Vumon
- Kisqali (200 MG Dose)-Vusion
- Kisqali (200 MG Dose)-Vyfemla
- Kisqali (200 MG Dose)-Vyleesi
- Kisqali (200 MG Dose)-Vyleesi Injection
- Kisqali (200 MG Dose)-VyLibra
- Vumerity-Kisqali (400 MG Dose)
- Vumerity-Kisqali (600 MG Dose)
- Vumerity-Kisqali Femara Co-Pack
- Vumerity-Kisqali Femara Co-Pack 200 mg-2.5 mg Dose
- Vumerity-Kisqali Femara Co-Pack 400 mg-2.5 mg Dose
- Vumerity-Kisqali Femara Co-Pack 600 mg-2.5 mg Dose